⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VKTX News
Viking Therapeutics, Inc
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
globenewswire.com
VKTX
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
prnewswire.com
ABCL
VKTX
HYFT
ABSI
NVDA
Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates
globenewswire.com
MRK
PFE
AZN
LLY
VKTX
STRT
Complicated Urinary Tract Infections Market Report, Analyzes Treatment Needs Across Elderly, Diabetic, and Immunosuppressed Populations
globenewswire.com
ABBV
PFE
GALT
VKTX
LPCN
ALGS
LLY
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
prnewswire.com
VKTX
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
prnewswire.com
VKTX
Form 8-K
sec.gov
VKTX
Viking Therapeutics to Participate at Upcoming Investor Conferences
prnewswire.com
VKTX
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
globenewswire.com
MRK
ABBV
VKTX
ALT
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
prnewswire.com
VKTX